WO2013089189A1 - Optical resolution method for bicyclic compound using hydroxysulfonic acid - Google Patents
Optical resolution method for bicyclic compound using hydroxysulfonic acid Download PDFInfo
- Publication number
- WO2013089189A1 WO2013089189A1 PCT/JP2012/082356 JP2012082356W WO2013089189A1 WO 2013089189 A1 WO2013089189 A1 WO 2013089189A1 JP 2012082356 W JP2012082356 W JP 2012082356W WO 2013089189 A1 WO2013089189 A1 WO 2013089189A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- general formula
- optically active
- salt
- active amine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 *C(C[C@]1C2)=C[C@]1C2=O Chemical compound *C(C[C@]1C2)=C[C@]1C2=O 0.000 description 4
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B57/00—Separation of optically-active compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/12—Formation of amino and carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
- C07C303/02—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/51—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition
- C07C45/52—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by pyrolysis, rearrangement or decomposition by dehydration and rearrangement involving two hydroxy groups in the same molecule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/78—Separation; Purification; Stabilisation; Use of additives
- C07C45/85—Separation; Purification; Stabilisation; Use of additives by treatment giving rise to a chemical modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/20—All rings being cycloaliphatic the ring system containing seven carbon atoms
Definitions
- the present invention relates to a bicyclic ⁇ -amino acid derivative or a pharmacologically acceptable salt thereof, particularly a compound having activity as an ⁇ 2 ⁇ ligand and an optically active process for producing an intermediate thereof.
- Non-Patent Document 1 Compounds that exhibit high affinity binding to the ⁇ 2 ⁇ subunit of the voltage-gated calcium channel have been shown to be effective, for example, in the treatment of neuropathic pain (eg, Non-Patent Document 1 and Non-Patent Document 1). Patent Document 2).
- ⁇ 2 ⁇ ligands are known as therapeutic agents for neuropathic pain, and examples of ⁇ 2 ⁇ ligands include gabapentin and pregabalin.
- ⁇ 2 ⁇ ligands such as these compounds are useful for the treatment of epilepsy, neuropathic pain and the like (for example, Patent Document 1).
- Other compounds are disclosed in, for example, Patent Document 2, Patent Document 3, Patent Document 4, and the like.
- Patent Literature 5 and Patent Literature as ⁇ 2 ⁇ ligands and methods for producing the same. 6 is reported.
- Patent Document 7 Examples of optical resolution of hydroxysulfonates have been reported (Patent Document 7, Non-Patent Document 3), but the structure is different from the compounds split according to the present invention.
- An object of the present invention is to provide a bicyclic ⁇ -amino acid derivative or a pharmacologically acceptable salt thereof, in particular, a compound having activity as an ⁇ 2 ⁇ ligand and an optically active method for producing an intermediate thereof. To do.
- Patent Document 5 or Patent Document 6 reports a method for producing compound 6 as described in Scheme 1.
- the inventors of the present application have paid attention to the method of stereocontrol of the asymmetric carbon in the production method of Compound 6, and have continued intensive research to develop an efficient method.
- optical splitting is performed in the process (Step 4) immediately before the final process, but it is possible to establish a more efficient manufacturing method by performing optical splitting in an early process. I thought it would be possible. That is, the problem to be solved by the present invention is to develop a production method in which an intermediate thereof is an optically active compound in an early step of the production of compound 6.
- the inventors of the present application continued intensive studies to solve this problem, and as a result, the problem was solved and the present invention was completed.
- R 1a a hydrogen atom or a C1-C6 alkyl group
- a racemic mixture of a compound having the general formula (I) and a compound having the general formula (II) is present in the presence of sulfur dioxide (sulfurous acid gas, hereinafter referred to as SO 2 gas), water, an optically active amine and a solvent.
- SO 2 gas sulfurous acid gas
- R 1 is a hydrogen atom or a C1-C6 alkyl group
- R 1 is a hydrogen atom or a C1-C6 alkyl group
- a process for producing a compound having the general formula (I). [3] The method according to [1] or [2], wherein R 1 is a hydrogen atom, a methyl group, or an ethyl group. [4] The method according to [2] or [3], wherein the optically active amine in (1) is any one selected from the group shown below.
- the amount of the optically active amine used in (1) is 0.3-0.7 or 0.8 with respect to the racemic mixture of the compound having the general formula (I) and the compound having the general formula (II).
- Any one selected from 1,2-dimethoxyethane, isopropyl ether, ethers such as tetrahydrofuran, highly polar solvents such as acetonitrile, esters such as ethyl acetate [7] [2]-[6] A method for producing a compound having the general formula (III) or a salt thereof, using the compound having the general formula (I) produced by the method.
- the present invention is useful for optically active production of bicyclic ⁇ -amino acid derivatives or pharmacologically acceptable salts thereof, particularly compounds having activity as ⁇ 2 ⁇ ligands and intermediates thereof.
- the present invention is efficient because it is a production method in which an intermediate is used as an optically active compound in an early step of the production.
- the C1-C6 alkyl group is a linear or branched alkyl group having 1-6 carbon atoms, for example, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group , A pentyl group, a hexyl group, and the like, preferably a methyl group, an ethyl group, and a propyl group.
- the compound having the general formula (I) or general formula (II) preferably a compound in which R 1 has a hydrogen atom, a methyl group or an ethyl group.
- Step (1) In the SO 2 gas used in the present invention, an excess amount is blown into the reaction solution with respect to the racemic mixture of the compound having the general formula (I) and the compound having the general formula (II). Added by.
- the water used in the present invention is preferably 0.8 to 1.2 equivalents, more preferably a racemic mixture of the compound having the general formula (I) and the compound having the general formula (II). Is 0.9-1.1 equivalent.
- the “optically active amine” used when producing the compound having the general formula (I) is preferably an optically active amine as shown in Table 1 below.
- the compound which has general formula (II) when manufacturing the compound which has general formula (II), what is necessary is just to use the enantiomer which has a configuration opposite to the optically active amine used when manufacturing the compound which has general formula (I).
- the amount of the optically active amine varies depending on the solvent used or the salt formation ratio with hydroxysulfonic acid, but with respect to the racemic mixture of the compound having the general formula (I) and the compound having the general formula (II), 0.3-0.7 or 0.8-1.2 equivalents are preferred, and 0.4-0.6 or 0.9-1.1 equivalents are more preferred.
- a compound having the general formula (I) or a compound having the general formula (II) can be produced by appropriately selecting the enantiomer of the optically active amine to be used.
- ethers such as 1,2-dimethoxyethane, isopropyl ether and tetrahydrofuran, highly polar solvents such as acetonitrile, and esters such as ethyl acetate are preferable, and 1,2-dimethoxyethane and acetonitrile are preferable. More preferred.
- the reaction temperature is desirably cooled to about 0 ° C., and when the temperature rises above room temperature, a salt may not be formed properly.
- the aqueous alkali solution used may be any aqueous alkaline solution that can return the salt to a free form, but it is preferable to use an aqueous sodium carbonate solution.
- the “salt” in the present invention is a compound or the like represented by the general formula (III), and forms a salt by reacting with an acid or a base by having an amino group and a carboxyl group in its structure. Says the salt.
- a compound having the general formula (III) may be left in the air or recrystallized to absorb moisture and have adsorbed water to form a hydrate. Such hydrates are also included in the salts of the present invention.
- the compound having the general formula (III) or a salt thereof exhibits activity as an ⁇ 2 ⁇ ligand, has an affinity for the ⁇ 2 ⁇ subunit of the voltage-gated calcium channel, pain, central nervous disorder, and others It is useful as an active ingredient of a pharmaceutical composition used for the treatment and / or prevention of disorders.
- 1,2-Dimethoxyethane (0.5 mL) was added to the obtained title compound (99.8 mg, 0.204 mmol), and the mixture was stirred at 0 ° C. for 12 hours, and then the crystals were filtered and cooled to 0 ° C. , 2-Dimethoxyethane, and dried under reduced pressure to obtain the title compound (70.7 mg, 90.2% ee) (yield 56.3% (N / N)).
- 1,2-Dimethoxyethane (0.5 mL) was added to the obtained title compound (96.7 mg, 0.231 mmol), and the mixture was stirred at room temperature for 12 hours, and then the crystals were filtered and cooled to 0 ° C. Washing with 2-dimethoxyethane and drying under reduced pressure gave the title compound (70.2 mg, 80.3% ee) (yield 59% (N / N)).
- 1,2-Dimethoxyethane (0.5 mL) was added to the obtained title compound (102 mg, 0.272 mmol), and the mixture was stirred at room temperature for 12 hours. The crystals were filtered and cooled to 0 ° C. Washing with dimethoxyethane and drying under reduced pressure gave the title compound (70.2 mg, 97.3% ee) (yield 58% (N / N)).
- Example 5 The optical purity of the optically active compound obtained in Example 1-4 was determined by the following method. About 10 mg of the amine salt described in the title of each example was taken and dissolved in 1 mL of 5% aqueous sodium carbonate solution, 5 mL of toluene was added, and the mixture was stirred at room temperature for about 1 hour. After standing, only the toluene layer was sampled and analyzed by HPLC (analysis conditions are as described below).
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
本発明は、二環性γ-アミノ酸誘導体又はその薬理学的に許容される塩、特に、α2δリガンドとして活性を有する化合物及びその中間体の光学活性な製造方法に関する。 The present invention relates to a bicyclic γ-amino acid derivative or a pharmacologically acceptable salt thereof, particularly a compound having activity as an α 2 δ ligand and an optically active process for producing an intermediate thereof.
電位依存性カルシウムチャネルのα2δサブユニットに対して高親和性結合を示す化合物は、例えば神経因性疼痛の治療において有効であることが明らかになっている(例えば、非特許文献1および非特許文献2参照)。 Compounds that exhibit high affinity binding to the α 2 δ subunit of the voltage-gated calcium channel have been shown to be effective, for example, in the treatment of neuropathic pain (eg, Non-Patent Document 1 and Non-Patent Document 1). Patent Document 2).
現在、神経因性疼痛の治療薬として数種類のα2δリガンドが知られており、α2δリガンドとしては、例えば、ガバペンチン、プレガバリンなどがある。これらの化合物のようなα2δリガンドは、てんかんおよび神経因性疼痛等の治療に有用である(例えば、特許文献1)。その他の化合物としては、例えば、特許文献2、特許文献3、特許文献4などに開示されている
また、出願人は、これまでにα2δリガンド及びその製造方法として、特許文献5及び特許文献6を報告している。
Currently, several types of α 2 δ ligands are known as therapeutic agents for neuropathic pain, and examples of α 2 δ ligands include gabapentin and pregabalin. Α 2 δ ligands such as these compounds are useful for the treatment of epilepsy, neuropathic pain and the like (for example, Patent Document 1). Other compounds are disclosed in, for example, Patent Document 2, Patent Document 3, Patent Document 4, and the like. Further, the applicant has previously described Patent Literature 5 and Patent Literature as α 2 δ ligands and methods for producing the same. 6 is reported.
ヒドロキシスルホン酸塩を光学分割している例は報告されているが(特許文献7、非特許文献3)、本発明によって分割される化合物とは構造が異なる。 Examples of optical resolution of hydroxysulfonates have been reported (Patent Document 7, Non-Patent Document 3), but the structure is different from the compounds split according to the present invention.
本発明は、二環性γ-アミノ酸誘導体又はその薬理学的に許容される塩、特に、α2δリガンドとして活性を有する化合物及びその中間体の光学活性な製造方法を提供することを目的とする。 An object of the present invention is to provide a bicyclic γ-amino acid derivative or a pharmacologically acceptable salt thereof, in particular, a compound having activity as an α 2 δ ligand and an optically active method for producing an intermediate thereof. To do.
特許文献5又は特許文献6には、Scheme1に記載のような化合物6の製造方法が報告されている。
本出願の発明者らは、化合物6の製造方法における不斉炭素の立体制御の方法に着目して、その効率的な方法を開発するために鋭意研究を続けてきた。これまでの製法では、最終工程の一つ前の工程(Step 4)で光学分割を行っているが、光学分割を早期の工程で実施することに、より効率的な製造方法を確立することが可能であろうと考えた。
すなわち、本発明が解決しようとする課題は、化合物6の製造の早期の工程において、その中間体を光学活性化合物とするような製造方法を開発することである。本出願の発明者らは、この課題を解決するために鋭意研究を継続し、その結果として課題を解決し、本発明を完成させた。
Patent Document 5 or Patent Document 6 reports a method for producing compound 6 as described in Scheme 1.
The inventors of the present application have paid attention to the method of stereocontrol of the asymmetric carbon in the production method of Compound 6, and have continued intensive research to develop an efficient method. In the conventional manufacturing method, optical splitting is performed in the process (Step 4) immediately before the final process, but it is possible to establish a more efficient manufacturing method by performing optical splitting in an early process. I thought it would be possible.
That is, the problem to be solved by the present invention is to develop a production method in which an intermediate thereof is an optically active compound in an early step of the production of compound 6. The inventors of the present application continued intensive studies to solve this problem, and as a result, the problem was solved and the present invention was completed.
[式中、各置換基は以下のように定義される。R1a:水素原子またはC1-C6アルキル基] [Wherein each substituent is defined as follows. R 1a : a hydrogen atom or a C1-C6 alkyl group]
本発明を以下に説明する。
[1] 一般式(I)を有する化合物又は一般式(II)を有する化合物を製造する方法であり、
The present invention will be described below.
[1] A method for producing a compound having the general formula (I) or a compound having the general formula (II),
(1)一般式(I)を有する化合物と一般式(II)を有する化合物とのラセミ混合物を、二酸化硫黄(亜硫酸ガス、以下SO2ガスと称する。)、水、光学活性アミン及び溶媒の存在下反応させた後、一般式(I’)を有する化合物又は一般式(II’)を有する化合物のどちらか一方を光学活性アミンとの塩の結晶として析出させて、 (1) A racemic mixture of a compound having the general formula (I) and a compound having the general formula (II) is present in the presence of sulfur dioxide (sulfurous acid gas, hereinafter referred to as SO 2 gas), water, an optically active amine and a solvent. After the lower reaction, either the compound having the general formula (I ′) or the compound having the general formula (II ′) is precipitated as a salt crystal with an optically active amine,
(2)その得られた一般式(I’)を有する化合物又は一般式(II’)を有する化合物のどちらか一方の塩の結晶をアルカリ水溶液で処理することによって、 (2) treating the obtained crystals of the salt of either the compound having the general formula (I ′) or the compound having the general formula (II ′) with an alkaline aqueous solution,
[各式中、R1:水素原子又はC1-C6アルキル基]
一般式(I)を有する化合物又は一般式(II)を有する化合物を製造する方法。
[In each formula, R 1 is a hydrogen atom or a C1-C6 alkyl group]
A method for producing a compound having the general formula (I) or a compound having the general formula (II).
本発明の好適な態様としては、以下の発明である。
[2] 一般式(I)を有する化合物を製造する方法であり、
Preferred embodiments of the present invention are the following inventions.
[2] A method for producing a compound having the general formula (I),
(1)一般式(I)を有する化合物と一般式(II)を有する化合物とのラセミ混合物を、SO2ガス、水、光学活性アミン及び溶媒の存在下反応させた後、一般式(I’)を有する化合物を光学活性アミンとの塩の結晶として析出させて、 (1) A racemic mixture of a compound having the general formula (I) and a compound having the general formula (II) is reacted in the presence of SO 2 gas, water, an optically active amine and a solvent, and then the general formula (I ′ ) As a crystal of a salt with an optically active amine,
(2)その得られた一般式(I’)を有する化合物の塩をアルカリ水溶液で処理することによって、 (2) treating the resulting salt of the compound having general formula (I ') with an aqueous alkaline solution,
[各式中、R1:水素原子又はC1-C6アルキル基]
一般式(I)を有する化合物を製造する方法。
[3] R1が、水素原子、メチル基又はエチル基である、[1]又は[2]に記載の方法。
[4] (1)における光学活性アミンが以下に示す群から選択されるいずれか1種である、[2]又は[3]に記載の方法。
[In each formula, R 1 is a hydrogen atom or a C1-C6 alkyl group]
A process for producing a compound having the general formula (I).
[3] The method according to [1] or [2], wherein R 1 is a hydrogen atom, a methyl group, or an ethyl group.
[4] The method according to [2] or [3], wherein the optically active amine in (1) is any one selected from the group shown below.
[5] (1)における光学活性アミンの使用量が、一般式(I)を有する化合物と一般式(II)を有する化合物とのラセミ混合物に対して、0.3-0.7又は0.8-1.2当量当量である、[1]-[4]から選択されるいずれか1項にに記載の方法。
[6] (1)における溶媒が以下に示す群から選択されるいずれか1種である、[1]-[5]から選択されるいずれか1項に記載の方法。
1,2-ジメトキシエタン、イソプロピルエーテル、テトラヒドロフランのようなエーテル類、アセトニトリルのような高極性溶媒、酢酸エチルのようなエステル類
[7] [2]-[6]から選択されるいずれか1項により製造された一般式(I)を有する化合物を用いて、一般式(III)を有する化合物又はその塩を製造する方法。
[5] The amount of the optically active amine used in (1) is 0.3-0.7 or 0.8 with respect to the racemic mixture of the compound having the general formula (I) and the compound having the general formula (II). The method according to any one of [1]-[4], which is 8-1.2 equivalent equivalents.
[6] The method according to any one of [1] to [5], wherein the solvent in (1) is any one selected from the group shown below.
Any one selected from 1,2-dimethoxyethane, isopropyl ether, ethers such as tetrahydrofuran, highly polar solvents such as acetonitrile, esters such as ethyl acetate [7] [2]-[6] A method for producing a compound having the general formula (III) or a salt thereof, using the compound having the general formula (I) produced by the method.
本発明は、二環性γ-アミノ酸誘導体又はその薬理学的に許容される塩、特に、α2δリガンドとして活性を有する化合物及びその中間体の光学活性な製造するために有用である。
本発明は、その製造の早期の工程において、その中間体を光学活性化合物とするような製造方法であることから効率的である。
The present invention is useful for optically active production of bicyclic γ-amino acid derivatives or pharmacologically acceptable salts thereof, particularly compounds having activity as α 2 δ ligands and intermediates thereof.
The present invention is efficient because it is a production method in which an intermediate is used as an optically active compound in an early step of the production.
C1-C6アルキル基とは、炭素数が1-6の直鎖又は分岐鎖のアルキル基であり、例えば、メチル基、エチル基、プロピル基、イソプロピル基、ブチル基、イソブチル基、sec-ブチル基、ペンチル基、ヘキシル基等があり、好適には、メチル基、エチル基、プロピル基である。 The C1-C6 alkyl group is a linear or branched alkyl group having 1-6 carbon atoms, for example, methyl group, ethyl group, propyl group, isopropyl group, butyl group, isobutyl group, sec-butyl group , A pentyl group, a hexyl group, and the like, preferably a methyl group, an ethyl group, and a propyl group.
一般式(I)又は一般式(II)を有する化合物として、好適には、R1が水素原子、メチル基又はエチル基を有する化合物である。 As the compound having the general formula (I) or general formula (II), preferably a compound in which R 1 has a hydrogen atom, a methyl group or an ethyl group.
(1)の工程について
本発明において使用されるSO2ガスは、一般式(I)を有する化合物と一般式(II)を有する化合物とのラセミ混合物に対して、過剰量を反応液中に吹き込むことによって加えられる。
Step (1) In the SO 2 gas used in the present invention, an excess amount is blown into the reaction solution with respect to the racemic mixture of the compound having the general formula (I) and the compound having the general formula (II). Added by.
本発明において使用される水は、一般式(I)を有する化合物と一般式(II)を有する化合物とのラセミ混合物に対して、好適には0.8-1.2当量であり、より好適には、0.9-1.1当量である。
本発明において、一般式(I)を有する化合物を製造する際に使用される「光学活性アミン」としては、以下のTable1に示すような光学活性アミンが好適である。
The water used in the present invention is preferably 0.8 to 1.2 equivalents, more preferably a racemic mixture of the compound having the general formula (I) and the compound having the general formula (II). Is 0.9-1.1 equivalent.
In the present invention, the “optically active amine” used when producing the compound having the general formula (I) is preferably an optically active amine as shown in Table 1 below.
Table1 Table1
さらに好適には、Table2に示す光学活性アミンである。
Table2
The optically active amine shown in Table 2 is more preferable.
Table2
なお、一般式(II)を有する化合物を製造する際には、一般式(I)を有する化合物を製造する際に使用される光学活性アミンと逆の立体配置を有するエナンチオマーを用いればよい。
光学活性アミンの使用量は、使用する溶媒によって又はヒドロキシスルホン酸との塩形成比率によって異なるが、一般式(I)を有する化合物と一般式(II)を有する化合物とのラセミ混合物に対して、0.3-0.7又は0.8-1.2当量が好適であり、0.4-0.6又は0.9-1.1当量がより好適である。
適宜、使用する光学活性アミンのエナンチオマーを選択することによって、一般式(I)を有する化合物又は一般式(II)を有する化合物を製造することができる。
溶媒としては、1,2-ジメトキシエタン、イソプロピルエーテル、テトラヒドロフランのようなエーテル類、アセトニトリルのような高極性溶媒、酢酸エチルのようなエステル類が好適であり、1,2-ジメトキシエタン及びアセトニトリルがより好適である。
反応温度は、0℃程度に冷却することが望ましく、室温よりも温度が上昇すると適切に塩が形成されなくなることがある。
(2)の工程について
使用されるアルカリ水溶液としては、塩をフリー体に戻すことができるアルカリ水溶液であればよいが、炭酸ナトリウム水溶液を用いるのが好適である。
一般式(I)を有する化合物又は一般式(II)を有する化合物を用いて、先に記載の特許文献6(WO 2010/110361)に記載の方法と同様に製造を行うことにより、一般式(III)又は一般式(III’)を有する化合物を製造することができる。
In addition, when manufacturing the compound which has general formula (II), what is necessary is just to use the enantiomer which has a configuration opposite to the optically active amine used when manufacturing the compound which has general formula (I).
The amount of the optically active amine varies depending on the solvent used or the salt formation ratio with hydroxysulfonic acid, but with respect to the racemic mixture of the compound having the general formula (I) and the compound having the general formula (II), 0.3-0.7 or 0.8-1.2 equivalents are preferred, and 0.4-0.6 or 0.9-1.1 equivalents are more preferred.
A compound having the general formula (I) or a compound having the general formula (II) can be produced by appropriately selecting the enantiomer of the optically active amine to be used.
As the solvent, ethers such as 1,2-dimethoxyethane, isopropyl ether and tetrahydrofuran, highly polar solvents such as acetonitrile, and esters such as ethyl acetate are preferable, and 1,2-dimethoxyethane and acetonitrile are preferable. More preferred.
The reaction temperature is desirably cooled to about 0 ° C., and when the temperature rises above room temperature, a salt may not be formed properly.
Step (2) The aqueous alkali solution used may be any aqueous alkaline solution that can return the salt to a free form, but it is preferable to use an aqueous sodium carbonate solution.
By using the compound having the general formula (I) or the compound having the general formula (II), and carrying out the production in the same manner as the method described in Patent Document 6 (WO 2010/110361) described above, the general formula ( Compounds having III) or general formula (III ′) can be prepared.
本発明における「塩」とは、一般式(III)で表される化合物等において、その構造中にアミノ基及びカルボキシル基を有することにより酸または塩基とを反応させることにより塩を形成するので、その塩をいう。 The “salt” in the present invention is a compound or the like represented by the general formula (III), and forms a salt by reacting with an acid or a base by having an amino group and a carboxyl group in its structure. Says the salt.
一般式(III)を有する化合物等は、大気中に放置したり、または、再晶析を行ったりすることにより、水分を吸収して吸着水が付き、水和物となる場合があり、そのような水和物も本発明の塩に包含される。 A compound having the general formula (III) may be left in the air or recrystallized to absorb moisture and have adsorbed water to form a hydrate. Such hydrates are also included in the salts of the present invention.
一般式(III)を有する化合物又はその塩は、α2δリガンドとして活性を示し、電位依存性カルシウムチャンネルのα2δサブユニットに対して親和性があり、痛み、中枢神経性障害、およびその他の障害の治療および/または予防に使用される医薬組成物の有効成分として有用である。 The compound having the general formula (III) or a salt thereof exhibits activity as an α 2 δ ligand, has an affinity for the α 2 δ subunit of the voltage-gated calcium channel, pain, central nervous disorder, and others It is useful as an active ingredient of a pharmaceutical composition used for the treatment and / or prevention of disorders.
(実施例1)
(1R,5S,6R)-3-エチル-6-ヒドロキシビシクロ[3.2.0]ヘプタ-3-エン-6-スルホン酸 (R)-1-フェニルエチルアミン(1:1)塩
Example 1
(1R, 5S, 6R) -3-Ethyl-6-hydroxybicyclo [3.2.0] hept-3-ene-6-sulfonic acid (R) -1-phenylethylamine (1: 1) salt
1,2-ジメトキシエタン(5mL)、(R)-1-フェニルエチルアミン(445mg、3.67mmol)、水(0.146mL、8.08mmol)の混合液に、20℃にてSO2ガスを約10分間吹き込んだ後、3-エチルビシクロ[3.2.0]ヘプタ-3-エン-6-オン(1.00g、7.34mmol)を添加した。20℃にて数分攪拌したのち、0℃に冷却してさらに4時間攪拌した。析出した結晶をろ過し、0℃に冷却した1,2-ジメトキシエタンにて洗浄、減圧乾燥し、標記化合物(691.4mg、27.8%ee)を得た(収率24%(N/N))。
1H NMR (500 MHz, DMSO-d6) d 1.02 (t, 3H, J=7.4 Hz), 1.46-1.49 (m, 1H), 1.48 (d, 3H, J=6.8 Hz), 1.91-1.93 (m, 1H), 2.02-2.12 (m. 2H), 2.36-2.41 (m, 2H), 2.53-2.58 (m, 1H), 3.47 (bs, 1H), 4.40 (q, 1H, J=6.8 Hz), 4.73 (bs, 1H), 5.27-5.29 (m, 1H), 7.36-7.48 (m, 5H), 8.01 (bs, 3H).
(実施例2)
(1R,5S,6R)-3-エチル-6-ヒドロキシビシクロ[3.2.0]ヘプタ-3-エン-6-スルホン酸 (R)-1-フェニルエチルアミン(1:2)塩
アセトニトリル(5mL)、(R)-1-フェニルエチルアミン(890mg、7.34mmol)、水(73.0μL、4.04mmol)の混合液に、20℃にてSO2ガスを約10分間吹き込んだ後、3-エチルビシクロ[3.2.0]ヘプタ-3-エン-6-オン(500mg、3.67mmol)を添加した。20℃にて数分攪拌したのち、0℃に冷却してさらに5時間攪拌した。析出した結晶をろ過し、0℃に冷却したアセトニトリル(5mL)にて洗浄、減圧乾燥し、標記化合物(599.6mg、59.9%ee)を得た(収率34%(N/G))。
To a mixture of 1,2-dimethoxyethane (5 mL), (R) -1-phenylethylamine (445 mg, 3.67 mmol), and water (0.146 mL, 8.08 mmol), SO 2 gas was added at 20 ° C. After blowing for 10 minutes, 3-ethylbicyclo [3.2.0] hept-3-en-6-one (1.00 g, 7.34 mmol) was added. After stirring at 20 ° C. for several minutes, the mixture was cooled to 0 ° C. and further stirred for 4 hours. The precipitated crystals were filtered, washed with 1,2-dimethoxyethane cooled to 0 ° C., and dried under reduced pressure to obtain the title compound (691.4 mg, 27.8% ee) (yield 24% (N / N)).
1 H NMR (500 MHz, DMSO-d6) d 1.02 (t, 3H, J = 7.4 Hz), 1.46-1.49 (m, 1H), 1.48 (d, 3H, J = 6.8 Hz), 1.91-1.93 (m , 1H), 2.02-2.12 (m. 2H), 2.36-2.41 (m, 2H), 2.53-2.58 (m, 1H), 3.47 (bs, 1H), 4.40 (q, 1H, J = 6.8 Hz), 4.73 (bs, 1H), 5.27-5.29 (m, 1H), 7.36-7.48 (m, 5H), 8.01 (bs, 3H).
(Example 2)
(1R, 5S, 6R) -3-Ethyl-6-hydroxybicyclo [3.2.0] hept-3-ene-6-sulfonic acid (R) -1-phenylethylamine (1: 2) salt Acetonitrile (5 mL ), (R) -1-phenylethylamine (890 mg, 7.34 mmol) and water (73.0 μL, 4.04 mmol) were blown with SO 2 gas at 20 ° C. for about 10 minutes, then 3- Ethylbicyclo [3.2.0] hept-3-en-6-one (500 mg, 3.67 mmol) was added. After stirring at 20 ° C. for several minutes, the mixture was cooled to 0 ° C. and further stirred for 5 hours. The precipitated crystals were filtered, washed with acetonitrile (5 mL) cooled to 0 ° C., and dried under reduced pressure to obtain the title compound (599.6 mg, 59.9% ee) (yield 34% (N / G)) ).
得られた標記化合物(99.8mg、0.204mmol)に1,2-ジメトキシエタン(0.5mL)を加え、0℃にて12時間攪拌した後、結晶をろ過し、0℃に冷却した1,2-ジメトキシエタンにて洗浄、減圧乾燥し、標記化合物(70.7mg、90.2%ee)を得た(収率56.3%(N/N))。
1H NMR (500 MHz, DMSO-d6) d 1.02 (t, 3H, J=7.4 Hz), 1.43 (d, 6H, J=6.7 Hz), 1.46-1.50 (m, 1H), 1.91-1.93 (m, 1H), 2.02-2.12 (m. 2H), 2.36-2.41 (m, 2H), 2.53-2.58 (m, 1H), 3.47 (bs, 1H), 4.30 (q, 2H, J=6.7 Hz), 5.27-5.29 (m, 1H), 7.32-7.46 (m, 10H).
(実施例3)
(1R,5S,6R)-3-エチル-6-ヒドロキシビシクロ[3.2.0]ヘプタ-3-エン-6-スルホン酸 (R)-1-(p-トリル)エチルアミン(1:1)塩
1,2-Dimethoxyethane (0.5 mL) was added to the obtained title compound (99.8 mg, 0.204 mmol), and the mixture was stirred at 0 ° C. for 12 hours, and then the crystals were filtered and cooled to 0 ° C. , 2-Dimethoxyethane, and dried under reduced pressure to obtain the title compound (70.7 mg, 90.2% ee) (yield 56.3% (N / N)).
1 H NMR (500 MHz, DMSO-d6) d 1.02 (t, 3H, J = 7.4 Hz), 1.43 (d, 6H, J = 6.7 Hz), 1.46-1.50 (m, 1H), 1.91-1.93 (m , 1H), 2.02-2.12 (m. 2H), 2.36-2.41 (m, 2H), 2.53-2.58 (m, 1H), 3.47 (bs, 1H), 4.30 (q, 2H, J = 6.7 Hz), 5.27-5.29 (m, 1H), 7.32-7.46 (m, 10H).
(Example 3)
(1R, 5S, 6R) -3-Ethyl-6-hydroxybicyclo [3.2.0] hept-3-ene-6-sulfonic acid (R) -1- (p-tolyl) ethylamine (1: 1) salt
1,2-ジメトキシエタン(5mL)、(R)-1-(p-トリル)エチルアミン(496mg、3.67mmol)、水(146μL、4.04mmol)の混合液に、20℃にてSO2ガスを約10分間吹き込んだ後、3-エチルビシクロ[3.2.0]ヘプタ-3-エン-6-オン(1.00g、7.34mmol)を添加した。20℃にて数分攪拌したのち、0℃に冷却してさらに5時間攪拌した。析出した結晶をろ過し、0℃に冷却した1,2-ジメトキシエタン(5mL)にて洗浄、減圧乾燥し標記化合物(582mg、57.4%ee)を得た(収率19%(N/N))。 To a mixture of 1,2-dimethoxyethane (5 mL), (R) -1- (p-tolyl) ethylamine (496 mg, 3.67 mmol), water (146 μL, 4.04 mmol) at 20 ° C. with SO 2 gas Was bubbled in for about 10 minutes before 3-ethylbicyclo [3.2.0] hept-3-en-6-one (1.00 g, 7.34 mmol) was added. After stirring at 20 ° C. for several minutes, the mixture was cooled to 0 ° C. and further stirred for 5 hours. The precipitated crystals were filtered, washed with 1,2-dimethoxyethane (5 mL) cooled to 0 ° C., and dried under reduced pressure to obtain the title compound (582 mg, 57.4% ee) (yield 19% (N / N)).
得られた標記化合物(96.7mg、0.231mmol)に1,2-ジメトキシエタン(0.5mL)を加え、室温にて12時間攪拌した後、結晶をろ過し、0℃に冷却した1,2-ジメトキシエタンにて洗浄、減圧乾燥し、標記化合物(70.2mg、80.3%ee)を得た(収率59%(N/N))。
1H NMR (500 MHz, DMSO-d6) d 1.02 (t, 3H, J=7.5 Hz), 1.44 (d, 3H, J=7.0 Hz), 1.46-1.49 (m, 1H), 1.91-1.93 (m, 1H), 2.02-2.12 (m. 2H), 2.31 (s, 3H), 2.36-2.41 (m, 2H), 2.53-2.58 (m, 1H), 3.47 (bs, 1H), 4.32 (q, 1H, J=6.8 Hz), 4.78 (bs, 1H), 5.29 (s, 1H), 7.23 (d, 2H, J=8.3Hz), 7.34 (d, 2H, J=8.3Hz), 7.75 (bs, 3H).
(実施例4)
(1R,5S,6R)-3-エチル-6-ヒドロキシビシクロ[3.2.0]ヘプタ-3-エン-6-スルホン酸 (R)-1-シクロヘキシルエチルアミン(1:1)塩
1,2-Dimethoxyethane (0.5 mL) was added to the obtained title compound (96.7 mg, 0.231 mmol), and the mixture was stirred at room temperature for 12 hours, and then the crystals were filtered and cooled to 0 ° C. Washing with 2-dimethoxyethane and drying under reduced pressure gave the title compound (70.2 mg, 80.3% ee) (yield 59% (N / N)).
1 H NMR (500 MHz, DMSO-d6) d 1.02 (t, 3H, J = 7.5 Hz), 1.44 (d, 3H, J = 7.0 Hz), 1.46-1.49 (m, 1H), 1.91-1.93 (m , 1H), 2.02-2.12 (m. 2H), 2.31 (s, 3H), 2.36-2.41 (m, 2H), 2.53-2.58 (m, 1H), 3.47 (bs, 1H), 4.32 (q, 1H , J = 6.8 Hz), 4.78 (bs, 1H), 5.29 (s, 1H), 7.23 (d, 2H, J = 8.3 Hz), 7.34 (d, 2H, J = 8.3 Hz), 7.75 (bs, 3H ).
(Example 4)
(1R, 5S, 6R) -3-Ethyl-6-hydroxybicyclo [3.2.0] hept-3-ene-6-sulfonic acid (R) -1-cyclohexylethylamine (1: 1) salt
アセトニトリル(10mL)、(R)-1-シクロヘキシルエチルアミン(934mg、7.34mmol)、水(146μL、4.04mmol)の混合液に、20℃にてSO2ガスを約10分間吹き込んだ後、3-エチルビシクロ[3.2.0]ヘプタ-3-エン-6-オン(1.00g、7.34mmol)を添加した。20℃にて数分攪拌したのち、0℃に冷却してさらに5時間攪拌した。析出した結晶をろ過し、0℃に冷却したアセトニトリル(5mL)にて洗浄、減圧乾燥し、標記化合物(1.03g、62.7%ee)を得た(収率37%(N/N))。 After SO 2 gas was blown into a mixture of acetonitrile (10 mL), (R) -1-cyclohexylethylamine (934 mg, 7.34 mmol) and water (146 μL, 4.04 mmol) at 20 ° C. for about 10 minutes, 3 -Ethylbicyclo [3.2.0] hept-3-en-6-one (1.00 g, 7.34 mmol) was added. After stirring at 20 ° C. for several minutes, the mixture was cooled to 0 ° C. and further stirred for 5 hours. The precipitated crystals were filtered, washed with acetonitrile (5 mL) cooled to 0 ° C., and dried under reduced pressure to obtain the title compound (1.03 g, 62.7% ee) (yield 37% (N / N)) ).
得られた標記化合物(102mg、0.272mmol)に1,2-ジメトキシエタン(0.5mL)を加え、室温にて12時間攪拌した後、結晶をろ過し、0℃に冷却した1,2-ジメトキシエタンにて洗浄、減圧乾燥し、標記化合物(70.2mg、97.3%ee)を得た(収率58%(N/N))。
1H NMR (500 MHz, DMSO-d6) d0.92-1.02 (m, 2H), 1.02 (t, 3H, J=7.4 Hz), 1.05-1.23 (m, 3H), 1.11 (d, 3H, J=6.7 Hz), 1.39-1.50 (m, 2H), 1.62-1.74 (m, 5H), 1.91-1.93 (m, 1H), 2.02-2.12 (m. 2H), 2.36-2.41 (m, 2H), 2.53-2.58 (m, 1H), 3.00 (td, 1H, J=6.7, 6.7 Hz), 3.47 (bs, 1H), 4.77 (bs, 1H), 5.27-5.29 (m, 1H), 7.58 (bs, 3H).
(実施例5)
実施例1-4で得られた光学活性化合物の光学純度は以下の方法で決定した。
各実施例の標題に記載のアミン塩を約10mgとり、5% 炭酸ナトリウム水溶液1mLに溶解させた後、トルエン5mLを加え室温にて約1時間攪拌した。静置後、トルエン層のみをサンプリングし、HPLC(分析条件は以下に記載の通り)にて分析した。
(HPLC分析条件)
カラム: CHIRALPAK AS-H 4.6×250mm; 40 ℃
波長: 305nm
流速: 1 mL/min
溶離液: IPA / hexane = 5 / 95
分析時間:15分間
保持時間:
(1S,5R)―3-エチルビシクロ[3.2.0]ヘプタ―3-エン―6―オン 4.8 min;
(1R,5S)―3-エチルビシクロ[3.2.0]ヘプタ―3-エン―6―オン 5.4 min
1,2-Dimethoxyethane (0.5 mL) was added to the obtained title compound (102 mg, 0.272 mmol), and the mixture was stirred at room temperature for 12 hours. The crystals were filtered and cooled to 0 ° C. Washing with dimethoxyethane and drying under reduced pressure gave the title compound (70.2 mg, 97.3% ee) (yield 58% (N / N)).
1 H NMR (500 MHz, DMSO-d6) d0.92-1.02 (m, 2H), 1.02 (t, 3H, J = 7.4 Hz), 1.05-1.23 (m, 3H), 1.11 (d, 3H, J = 6.7 Hz), 1.39-1.50 (m, 2H), 1.62-1.74 (m, 5H), 1.91-1.93 (m, 1H), 2.02-2.12 (m. 2H), 2.36-2.41 (m, 2H), 2.53-2.58 (m, 1H), 3.00 (td, 1H, J = 6.7, 6.7 Hz), 3.47 (bs, 1H), 4.77 (bs, 1H), 5.27-5.29 (m, 1H), 7.58 (bs, 3H).
(Example 5)
The optical purity of the optically active compound obtained in Example 1-4 was determined by the following method.
About 10 mg of the amine salt described in the title of each example was taken and dissolved in 1 mL of 5% aqueous sodium carbonate solution, 5 mL of toluene was added, and the mixture was stirred at room temperature for about 1 hour. After standing, only the toluene layer was sampled and analyzed by HPLC (analysis conditions are as described below).
(HPLC analysis conditions)
Column: CHIRALPAK AS-H 4.6 × 250mm; 40 ° C
Wavelength: 305nm
Flow rate: 1 mL / min
Eluent: IPA / hexane = 5/95
Analysis time: 15 minutes Retention time:
(1S, 5R) -3-Ethylbicyclo [3.2.0] hept-3-en-6-one 4.8 min;
(1R, 5S) -3-Ethylbicyclo [3.2.0] hept-3-en-6-one 5.4 min
Claims (7)
(1)一般式(I)を有する化合物と一般式(II)を有する化合物とのラセミ混合物を、二酸化硫黄(亜硫酸ガス、以下SO2ガスと称する。)、水、光学活性アミン及び溶媒の存在下反応させた後、一般式(I’)を有する化合物又は一般式(II’)を有する化合物のどちらか一方を光学活性アミンとの塩の結晶として析出させて、
(2)その得られた一般式(I’)を有する化合物又は一般式(II’)を有する化合物のどちらか一方の塩の結晶をアルカリ水溶液で処理することによって、
[各式中、R1:水素原子又はC1-C6アルキル基]
一般式(I)を有する化合物又は一般式(II)を有する化合物を製造する方法。 A method for producing a compound having the general formula (I) or a compound having the general formula (II),
(1) A racemic mixture of a compound having the general formula (I) and a compound having the general formula (II) is present in the presence of sulfur dioxide (sulfurous acid gas, hereinafter referred to as SO 2 gas), water, an optically active amine and a solvent. After the lower reaction, either the compound having the general formula (I ′) or the compound having the general formula (II ′) is precipitated as a salt crystal with an optically active amine,
(2) By treating the resulting salt crystals of either the compound having the general formula (I ′) or the compound having the general formula (II ′) with an alkaline aqueous solution,
[In each formula, R 1 is a hydrogen atom or a C1-C6 alkyl group]
A method for producing a compound having the general formula (I) or a compound having the general formula (II).
(1)一般式(I)を有する化合物と一般式(II)を有する化合物とのラセミ混合物を、SO2ガス、水、光学活性アミン及び溶媒の存在下反応させた後、一般式(I’)を有する化合物を光学活性アミンとの塩の結晶として析出させて、
(2)その得られた一般式(I’)を有する化合物の塩をアルカリ水溶液で処理することによって、
[各式中、R1:水素原子又はC1-C6アルキル基]
一般式(I)を有する化合物を製造する方法。 A process for producing a compound having the general formula (I)
(1) A racemic mixture of a compound having the general formula (I) and a compound having the general formula (II) is reacted in the presence of SO 2 gas, water, an optically active amine and a solvent, and then the general formula (I ′ ) As a crystal of a salt with an optically active amine,
(2) By treating the obtained salt of the compound having the general formula (I ′) with an alkaline aqueous solution,
[In each formula, R 1 is a hydrogen atom or a C1-C6 alkyl group]
A process for producing a compound having the general formula (I).
The method according to claim 2 or 3, wherein the optically active amine in (1) is any one selected from the group shown below.
1,2-ジメトキシエタン、イソプロピルエーテル、テトラヒドロフランのようなエーテル類、アセトニトリルのような高極性溶媒、酢酸エチルのようなエステル類 The method according to any one of claims 1 to 5, wherein the solvent in (1) is any one selected from the group shown below.
1,2-dimethoxyethane, ethers such as isopropyl ether and tetrahydrofuran, highly polar solvents such as acetonitrile, esters such as ethyl acetate
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011-275297 | 2011-12-16 | ||
| JP2011275297 | 2011-12-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2013089189A1 true WO2013089189A1 (en) | 2013-06-20 |
Family
ID=48612630
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP2012/082356 Ceased WO2013089189A1 (en) | 2011-12-16 | 2012-12-13 | Optical resolution method for bicyclic compound using hydroxysulfonic acid |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2013089189A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018517768A (en) * | 2015-05-27 | 2018-07-05 | ノヴァッセイ ソシエテ アノニムNovassay Sa | Separation of enantiomers of 3-bicyclo [3.2.0] hept-3-en-6-oneene |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4479974B2 (en) * | 2007-09-28 | 2010-06-09 | 第一三共株式会社 | Bicyclic γ-amino acid derivatives |
| WO2010084798A1 (en) * | 2009-01-21 | 2010-07-29 | 第一三共株式会社 | Tricyclic compound |
| WO2012169474A1 (en) * | 2011-06-08 | 2012-12-13 | 第一三共株式会社 | Method for producing bicyclic compound via iminium salt |
-
2012
- 2012-12-13 WO PCT/JP2012/082356 patent/WO2013089189A1/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4479974B2 (en) * | 2007-09-28 | 2010-06-09 | 第一三共株式会社 | Bicyclic γ-amino acid derivatives |
| WO2010084798A1 (en) * | 2009-01-21 | 2010-07-29 | 第一三共株式会社 | Tricyclic compound |
| WO2012169474A1 (en) * | 2011-06-08 | 2012-12-13 | 第一三共株式会社 | Method for producing bicyclic compound via iminium salt |
Non-Patent Citations (2)
| Title |
|---|
| EMANUELA MAROTTA ET AL., TETRAHEDRON LETTERS, vol. 35, no. 18, 1994, pages 2949 - 2950 * |
| SUJU P. MATHEW ET AL., ANGEWANDTE CHEMIE INTERNATIONAL EDITION, vol. 43, 2004, pages 3317 - 3321 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018517768A (en) * | 2015-05-27 | 2018-07-05 | ノヴァッセイ ソシエテ アノニムNovassay Sa | Separation of enantiomers of 3-bicyclo [3.2.0] hept-3-en-6-oneene |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11897843B2 (en) | Process for the preparation of enantiomerically enriched 3-aminopiperidine | |
| CN104755456A (en) | Method for producing optically active bicyclic [gamma]-amino acid derivative | |
| TW201708191A (en) | Novel processes for the preparation of prostaglandin amides | |
| WO2008067752A1 (en) | A process for preparing optical pure milnacipran and its pharmaceutically accepted salts | |
| WO2010067824A1 (en) | Process for producing optically active carboxylic acid | |
| JP4257574B2 (en) | Synthesis of R (+) α-lipoic acid | |
| JP2009062360A (en) | Method for producing cinacalcet | |
| JP2009062360A6 (en) | Cinacalcet manufacturing method | |
| WO2013089189A1 (en) | Optical resolution method for bicyclic compound using hydroxysulfonic acid | |
| RS20080279A (en) | Preparation of gamma-amino acids having affinity for the alpha-2-delta protein | |
| US8183408B2 (en) | Process for production of N-carbamoyl-tert-leucine | |
| JP2013245215A (en) | Method for producing optically active bicyclic compound based on asymmetric cyclization reaction | |
| EP3081554B1 (en) | Method for preparing silodosin and intermediate thereof | |
| US5880296A (en) | Method for preparing an optically pure benzofuran carboxylic acid and use thereof for preparing efaroxan | |
| WO2011158720A1 (en) | Method for producing (1r, 2s)-1-amino-2-vinyl cyclopropane carboxylic acid ester that has improved optical purity | |
| KR101755291B1 (en) | Process for the preparation of thyroid hormones and salts thereof | |
| RU2529996C2 (en) | Method for enantioselective synthesis of (s)-pregabalin | |
| AU2017232377A1 (en) | Process for converting S-enantiomer to its racemic form | |
| EP2805936A1 (en) | Process for preparing levomilnacipran HCL | |
| US6346649B1 (en) | Process for the recovery and recycle of D-tartaric acid | |
| US6392086B1 (en) | Intermediates and process for producing fluorine-containing amino acid compound by using the same | |
| CN104649948B (en) | Cilastatin calcium crystal, preparation method and application thereof | |
| JP6234999B2 (en) | Process for preparing optically active 3,3-diphenylpropylamine | |
| JP2003137835A (en) | Method for producing (r)-3-hydroxy-3-(2-phenyl)hexanoic acid | |
| GB2375109A (en) | Process for preparing bicyclic amino acid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12858519 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 12858519 Country of ref document: EP Kind code of ref document: A1 |
|
| NENP | Non-entry into the national phase |
Ref country code: JP |